Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.

摘要: BACKGROUND: The aim of this study was to assess the role systemic treatment after whole-brain radiotherapy (WBRT) in immunohistochemically defined biological subsets breast cancer patients with brain metastases. METHODS: group 420 consecutive metastases treated at same institution between years 2003 2009 analyzed. Patients were divided into 4 subsets, based on levels estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) receptors, labeled as luminal A, B, HER2, triple-negative. Survival from without WBRT calculated subsets. RESULTS: In entire group, median survival 3 10 months, respectively (P < .0001). triple-negative subset, months ¼ .16), A it 12 .003). B further treatment, chemotherapy and/or hormonal therapy, therapy targeted 9 15 HER2 6 13 No significant response noted population. CONCLUSIONS: Systemic ordered WBRT, appears improve subtypes. Targeted found have an additional positive impact survival. cancer, be less clear, therefore issue requires investigation. Cancer 2010;116:4238–47. V C 2010 American Society.